Cited by 2,611Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Type 2 diabetes mellitus

DeFronzo, Ralph A., Ferrannini, Ele, Groop, Leif, Henry, Robert R., Herman, William H., Holst, Jens Juul, Hu, Frank B., Kahn, C. Ronald +5 more·2015·Nature Reviews Disease Primers

Abstract

Type 2 diabetes mellitus (T2DM) is an expanding global health problem, closely linked to the epidemic of obesity. Individuals with T2DM are at high risk for both microvascular complications (including retinopathy, nephropathy and neuropathy) and macrovascular complications (such as cardiovascular comorbidities), owing to hyperglycaemia and individual components of the insulin resistance (metabolic) syndrome. Environmental factors (for example, obesity, an unhealthy diet and physical inactivity) and genetic factors contribute to the multiple pathophysiological disturbances that are responsible for impaired glucose homeostasis in T2DM. Insulin resistance and impaired insulin secretion remain the core defects in T2DM, but at least six other pathophysiological abnormalities contribute to the dysregulation of glucose metabolism. The multiple pathogenetic disturbances present in T2DM dictate that multiple antidiabetic agents, used in combination, will be required to maintain normoglycaemia. The treatment must not only be effective and safe but also improve the quality of life. Several novel medications are in development, but the greatest need is for agents that enhance insulin sensitivity, halt the progressive pancreatic β-cell failure that is characteristic of T2DM and prevent or reverse the microvascular complications. For an illustrated summary of this Primer, visit: http://go.nature.com/V2eGfN.

Integrity signals

Registry

Crossref · 10.1038/nrdp.2015.19

Cites

414 of 414 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., Simonson, D. C., Testa, M. A., & Weiss, R.
Affiliations
  • The University of Texas at San Antonio Health Science Center (US)
  • Istituto di Fisiologia Clinica (IT)
  • Lund University (SE)
  • University of California San Diego (US)
  • University of Michigan (US)
  • University of Copenhagen (DK)
  • Brigham and Women's Hospital (US)
  • Joslin Diabetes Center (US)
  • Hadassah Medical Center (IL)
  • Howard Hughes Medical Institute (US)
  • Harvard University (US)
  • Hebrew University of Jerusalem (IL)
Corresponding author
DeFronzo, Ralph A.
Venue
Nature Reviews Disease Primers
Published
2015-07-23
Volume
1
Issue
1
Pages
15019-15019
ISSN
2056-676X (ISSN-L)
OpenAlex
W44929223
Cited by
2,611
References
414
Citations by year
2026: 301 · 2025: 372 · 2024: 375 · 2023: 337 · 2022: 305 · 2021: 263 · 2020: 176 · 2019: 156 · 2018: 75 · 2017: 34 · 2016: 19 · 2015: 26 · 2014: 35 · 2013: 26 · 2012: 20
FWCI
7.76
Type
journal article
Language
en
Open access
closed
Locations
  • Nature Reviews Disease Primers (publishedVersion)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (R24DK085610, R01DK049230, R01DK031036, R01DK058845, P30DK046200, R01DK040936, R01DK033201, P30DK092926, P30DK036836, R01DK082659, R01DK024092)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, obesity, insulin resistance, impaired glucose homeostasis, impaired insulin secretion, pancreatic beta-cell failure, microvascular complications, macrovascular complications, cardiovascular comorbidity, antidiabetic drugs, insulin sensitizers, pathophysiology
MeSH terms
Blood Glucose, Diabetes Mellitus, Type 2, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin, Insulin Resistance, Metabolic Syndrome, Insulin-Secreting Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review